RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, announced plans to participate in the upcoming virtual SVB Leerink Global Healthcare Conference.
ALISO VIEJO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced plans to participate in the upcoming virtual SVB Leerink Global Healthcare Conference.
RxSight’s management is scheduled to participate in a fireside chat Thursday, February 17, 2022, at 12:40pm PT / 3:40pm ET. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: https://investors.rxsight.com/.
About RxSight, Inc.
RxSight, Inc. is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The LAL now features ActivShield™ technology, a revolutionary UV protection layer built into the lens. Additional information about RxSight can be found at www.rxsight.com.
Investor Relations Contact:
Philip Taylor
Gilmartin Group
415.937.5406
IR@rxsight.com
Company Contact:
Shelley Thunen
RxSight, Inc.
949-521-7830
IR@rxsight.com
